Latest Transplant rejection Stories
Cells found naturally in the body may help prevent the rejection of an organ transplant. Research shows new cell therapy could also eliminate a transplant patientâ€™s need for life-long medication and could help their transplant last longer.
In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug â€“ at one-half to one-fifth the price â€“ is as safe and effective as the other two.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells â€“ also known as "suppressor cells."
Researchers at King's College London have used cells found naturally in the body, to re-educate the immune system to prevent rejection of an organ transplant while remaining capable of fighting infections and cancer.
DURHAM, N.C., May 4, 2011 /PRNewswire/ -- Argos Therapeutics today announced that its immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for renal and heart transplantation.
Studies of the small sea squirt may ultimately help solve the problem of rejection of organ and bone marrow transplants in humans, according to scientists at UC Santa Barbara.
Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney.
For the first time, scientists at Toronto General Hospital, University Health Network have shown in a clinical trial that the Toronto XVIVO System can safely and effectively treat, re-assess and improve the function of high-risk donor lungs so that they can be successfully transplanted into patients.
SAN DIEGO, April 13, 2011 /PRNewswire/ -- The engineering of replacement tissue shows promise to dramatically impact the treatment of patients with end stage heart failure.
EXTON, Pa., March 29, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor [Human] for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants.
- To swell, as grain or wood with water.